Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 42Small Cell Lung Carcinoma 19Breast Neoplasms 16Sarcoma 12Lung Neoplasms 9Esophageal Squamous Cell Carcinoma 7Carcinoma, Hepatocellular 7Thyroid Neoplasms 6Stomach Neoplasms 6Nasopharyngeal Carcinoma 6Esophageal Neoplasms 6Ovarian Neoplasms 5NSCLC 5Carcinoma 5Triple Negative Breast Neoplasms 4Pheochromocytoma 4Pancreatic Neoplasms 4Neoplasm Metastasis 4Colorectal Neoplasms 4Carcinoma, Ovarian Epithelial 4Recurrence 3Paraganglioma 3Neoplasms 3Glioma 3Cholangiocarcinoma 3Brain Neoplasms 3Biliary Tract Neoplasms 3Uterine Cervical Neoplasms 2Urogenital Neoplasms 2Platinum-resistant Ovarian Cancer 2

Interventions

Pemetrexed 2rofecoxib 1pembrolizumab 1paclitaxel poliglumex 1osimertinib 1aumolertinib 1atezolizumab 1anlotinib 1Radiosurgery 1RO5126766 1Nivolumab 1Gemcitabine 1Drug Therapy 1Cisplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Advanced Non-small Cell Lung Cancer × anlotinib × Clear all
NCT06043973 2023-09-21

Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance

Qianfoshan Hospital

Phase 3 Recruiting
98 enrolled
Thoracic

Advanced Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡